coronavir
infect
associ
respiratori
tract
diseas
proteas
pro
coronavirus
requir
proteolyt
process
polyprotein
viral
replic
promis
target
develop
drug
coronavir
infect
design
synthes
four
nitrilebas
peptidomimet
inhibitor
differ
ntermin
protect
group
differ
peptid
length
examin
inhibitori
effect
invitro
enzymat
activ
pro
severeacuterespiratorysyndromecoronaviru
ic
valu
inhibitor
rang
mm
demonstr
nitril
warhead
effect
inactiv
pro
autocleavag
process
best
inhibitor
cbzavlqcn
ntermin
carbobenzyloxi
group
potent
inhibitor
test
crystal
structur
enzymeeinhibitor
complex
show
nitril
warhead
inhibit
pro
form
coval
bond
catalyt
residu
avlq
peptid
form
number
favour
interact
substratebind
pocket
show
peptidomimet
inhibitor
cbzavlqcn
broadspectrum
inhibit
pro
human
coronaviru
strain
infecti
bronchiti
viru
ic
valu
rang
mm
detect
inhibit
summari
shown
nitrilebas
peptidomimet
inhibitor
effect
pro
inhibit
pro
broad
rang
coronavirus
result
provid
insight
futur
design
drug
could
serv
first
line
defenc
coronavir
infect
coronavirus
cov
caus
number
respiratori
tract
gastroenter
diseas
human
anim
coronavirus
classifi
three
main
group
alphacoronaviru
group
betacoronaviru
group
gammacoronaviru
group
group
subdivid
group
addit
sarscov
group
caus
outbreak
pneumonia
four
human
group
strain
associ
respiratori
tract
diseas
case
report
singlestrand
rna
genom
cov
encod
two
polyprotein
process
least
matur
protein
papainlik
proteas
proteas
pro
inhibit
proteolyt
process
reduc
viral
replic
viralinduc
cytotox
effect
abil
coronavirus
gener
novel
strain
high
virul
high
frequenc
mutat
recombin
remain
potenti
threat
human
health
therefor
desir
develop
broadspectrum
drug
combat
kind
coronaviru
infect
pro
essenti
viral
replic
activesit
structur
conserv
proteas
attract
drug
target
develop
broadspectrum
inhibitor
sarscov
pro
inactiv
peptidomimet
inhibitor
compos
substratelik
peptid
reactiv
warhead
aldehyd
michael
acceptor
halomethyl
keton
epoxid
peptid
interact
substratebind
cleft
proteas
form
noncoval
complex
warhead
coval
link
catalyt
cystein
residu
inhibit
enzym
studi
shown
nitril
group
effect
warhead
pro
base
autocleavag
sequenc
sarscov
pro
tsavlqi
four
nitrilebas
inhibitor
differ
length
peptid
sequenc
protect
group
design
synthes
shown
inhibitor
effect
pro
six
differ
strain
cov
ic
valu
mm
rang
crystal
structur
four
enzymeeinhibitor
complex
determin
reveal
mechan
inhibit
enzymeeinhibitor
interact
base
autocleavag
tetrapeptid
sequenc
avlq
sarscov
pro
three
nitrilebas
inhibitor
differ
protect
group
mic
tertbutyloxycarbonyl
boc
carboxybenzyl
cbz
synthes
scheme
proteas
activ
presenc
inhibitor
measur
use
fluorescentprotein
substrat
describ
previous
ic
valu
micavlqcn
bocavlqcn
cbzavlqcn
ae
ae
ae
mm
respect
fig
interestingli
inhibitor
cbz
protect
group
potent
inhibitor
test
test
effect
increas
length
peptidomimet
inhibitor
synthes
hexapeptid
inhibitor
cbztsavlqcn
ic
valu
inhibitor
ae
mm
fig
suggest
increas
length
inhibitor
improv
inhibit
cbz
group
posit
may
respons
higher
potenc
cbzavlqcn
better
understand
enzymeeinhibitor
interact
determin
crystal
structur
sarscov
pro
complex
four
inhibitor
resolut
tabl
supplementari
data
pro
form
dimer
crystal
structur
inhibitor
occupi
substrat
bind
site
protom
electron
densiti
observ
tetrapeptid
alaevaleleuegln
posit
inhibitor
complex
fig
supplementari
materi
overlay
inhibitor
structur
demonstr
tetrapeptid
adopt
conform
bound
pro
hand
protect
group
micavlqcn
cbztsavlqcn
disord
observ
electron
densiti
scheme
reaction
scheme
nitrilebas
peptidomimet
inhibitor
synthesi
step
coupl
peptid
use
n
n
dicyclohexylcarbodiimid
nhydroxysuccinimid
step
b
coupl
peptid
mix
anhydrid
method
step
c
deprotect
benzyl
carbam
use
palladium
charcoal
step
deprotect
boc
trt
pbf
group
tertiari
butyl
ester
use
trifluoroacet
acid
step
e
transform
primari
amid
nitril
use
trifluoroacet
anhydrid
final
product
highlight
dash
box
sarscov
catalyt
dyad
consist
inhibitor
coval
bond
thiol
group
via
carbon
atom
nitril
warhead
fig
mechan
consist
observ
cystein
proteas
side
chain
occupi
subsit
respect
sarscov
pro
sidechain
point
toward
solvent
fig
number
hydrogen
bond
involv
enzymeeinhibitor
interact
side
chain
hydrogenbond
backbon
atom
sidechain
backbon
amid
group
form
hydrogen
bond
hydrogen
bond
help
residu
adopt
bstrand
like
conform
fig
noteworthi
aromat
ring
cbz
group
dock
pocket
ring
form
favour
hydrophob
interact
fig
extra
interact
absent
enzymeeinhibitor
complex
may
enhanc
bind
affin
pro
increas
potenc
cbzavlqcn
inhibitor
next
test
cbzavlqcn
inhibitor
broadspectrum
inhibit
pro
differ
group
coronavirus
measur
compar
ic
valu
cbzavlqcn
pro
human
coronaviru
hcov
strain
group
group
group
group
sarscov
group
infecti
bronchiti
viru
ibv
group
result
show
cbzavlqcn
inhibit
pro
test
valu
ic
rang
mm
fig
contrast
cbzavlqcn
observ
inhibit
effect
mm
fig
supplementari
materi
suggest
inhibitor
specif
pro
coronavirus
structur
pro
group
similar
model
studi
suggest
cbzavlqcn
inhibitor
fit
nice
activ
site
pro
group
coronavirus
inhibit
proteas
via
mechan
fig
supplementari
materi
studi
shown
nitrilebas
peptidomimet
inhibitor
display
broadspectrum
inhibit
pro
group
coronavirus
crystal
structur
enzyme
inhibitor
complex
provid
interest
insight
design
peptidomimet
inhibitor
first
enzymeeinhibitor
bind
mainli
determin
tetrapeptid
sequenc
avlq
suggest
consist
observ
extend
length
inhibitor
hexapeptid
cbztsavlqcn
improv
inhibit
fig
second
found
cbz
protect
group
nterminu
tetrapeptid
result
fold
increas
potenc
cbzavlqcn
inhibitor
inhibitor
test
observ
suggest
modif
peptidomimet
eg
crosslink
cbz
group
may
improv
efficaci
inhibit
high
recombin
frequenc
among
rna
genom
cov
develop
broadspectrum
inhibitor
attract
strategi
combat
infect
kind
cov
shown
nitrilebas
inhibitor
cbzavlqcn
inhibit
pro
group
cov
test
ic
valu
mm
rang
nitrilebas
proteas
inhibitor
eg
odanacatib
vildagliptin
success
clinic
applic
work
demonstr
inhibitor
describ
studi
may
serv
lead
developmentof
antivir
drug
target
broadspectrum
coronavirus
reaction
scheme
inhibitor
synthesi
summar
scheme
acid
micoh
n
n
dcc
nhydroxysuccinimid
hosu
purchas
sigmaealdrich
ident
final
product
verifi
h
nuclear
magnet
reson
mass
spectrometri
analysi
part
stir
suspens
nprotectedamino
acidoh
nprotectedpeptideoh
equiv
hosu
equiv
anhydr
tetrahydrofuran
thf
mlmmol
dcc
equiv
thf
ad
solut
c
reaction
mixtur
stir
min
temperatur
h
c
n
n
remov
filtrat
filtrat
collect
part
amino
acid
dissolv
thfh
vv
ph
solut
adjust
k
co
filtrat
part
ad
solut
c
mixtur
stir
min
c
overnight
c
solvent
evapor
vacuo
ph
residu
adjust
acid
citric
acid
c
extract
ethyl
acet
etoac
combin
extract
wash
brine
dri
mgso
filter
evapor
vacuo
residu
purifi
flash
chromatographi
silica
gel
give
desir
compound
nprotectedamino
acidoh
nprotectedpeptideoh
equiv
dissolv
thf
cool
c
stir
solut
nmethylmorpholin
nmm
equiv
isobutylchloroform
equiv
ad
consecut
precipit
nmethylmorpholin
hydrochlorid
amin
equiv
ad
mixtur
allow
warm
c
within
min
stir
addit
min
solvent
remov
reduc
pressur
residu
dissolv
etoac
solut
wash
h
satur
nahco
citric
acid
brine
solvent
dri
mgso
evapor
crude
residu
purifi
flash
column
chromatographi
give
product
stir
solut
benzyl
carbam
equiv
meoh
palladium
charcoal
benzyl
carbamatepalladium
charcoal
mg
ad
solut
evacu
place
h
atm
stir
h
reaction
monitor
thin
layer
chromatographi
tlc
suspens
filter
celit
wash
meoh
filtrat
concentr
reduc
pressur
afford
desir
amin
stir
solut
start
materi
equiv
ch
cl
tfa
equiv
ad
solut
stir
c
monitor
tlc
ch
cl
tfa
solvent
remov
reduc
pressur
residu
dilut
toluen
solvent
remov
reduc
pressur
stir
cold
solut
c
primari
amid
equiv
dri
thf
et
n
equiv
trifluoroacet
anhydrid
equiv
ad
min
solut
allow
warm
c
min
reaction
quench
h
thf
remov
reduc
pressur
product
extract
etoac
combin
extract
wash
satur
nahco
citric
acid
brine
dri
mgso
filter
evapor
vacuo
residu
purifi
flash
chromatographi
silica
gel
give
desir
compound
identif
product
nmr
mass
spectrometri
micavlqcn
compound
synthes
follow
procedur
describ
section
product
purifi
flash
chromatographi
silica
gel
afford
target
compound
yield
r
f
etoacmeoh
detail
procedur
product
pro
fluoresc
substrat
proteas
assay
pro
describ
previous
pro
mm
premix
mm
inhibitor
min
follow
addit
mm
substrat
decay
fluoresc
nm
fit
singleexponenti
decay
yield
observ
rate
constant
k
ob
k
ob
pro
valu
k
ob
pro
differ
concentr
inhibitor
normal
without
inhibitor
determin
rel
proteas
activ
fit
fourparamet
logist
equat
obtain
ic
valu
sarscov
pro
crystal
c
use
hangingdropvapourdiffus
method
mix
mgml
pro
ratio
mm
nmorpholino
ethanesulfon
acid
ph
wv
polyethylen
glycol
vv
glycerol
vv
dmso
mm
ethylenediaminetetraacet
acid
mm
dithiothreitol
singl
crystal
transfer
ml
mother
liquor
mm
inhibitor
incub
c
overnight
crystal
cryoprotect
vv
glycerol
diffract
data
collect
k
inhous
rigaku
fre
xray
sourc
phase
solv
molecular
replac
model
built
interact
program
coot
refin
phenix
